Navigation Links
BioMS Medical to participate in panel session at Bio International Convention 2009
Date:5/14/2009

- "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration" -

Toronto Stock Exchange Symbol: MS

EDMONTON, May 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Richard Brown, Vice President, Commercial Development, BioMS Medical and Mr. Jack Tupman, Senior Director, Corporate Business Development, Eli Lilly and Company, will take part in a Technology Transfer/Licensing session at the BIO International Convention 2009 in Atlanta, Georgia entitled "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration."

Also participating in the panel session will be Mr. Nitin Kaushal, Director, Healthcare Investment Banking, Desjardins Securities and Mr. Jeremy Webster, Senior VP & Director Deloitte & Touche, LLP. The moderator for the session will be Ms. Cheryl Reicin, Partner, Torys LLP.

    WHEN:     Thursday May 21st at 8:00am (Eastern Time)

    WHERE:    Room B316, Georgia World Congress Center, Atlanta, Georgia

    BioMS Medical will also provide a corporate presentation at the Business
Forum at 9:40am (Eastern Time) on Wednesday May 20th.

    About BIO International Convention
    ----------------------------------
    The BIO International Convention, hosted by the Biotechnology Industry
Organization, is the largest global event for the biotechnology industry and
attracts the biggest names in biotech, offers key networking and partnering
opportunities, and provides insights and inspiration on major trends affecting
the industry. For more information visithttp://convention.bio.org/.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. BioMS Medical to present at Alberta Economic Forum in Geneva
3. BioMS Medical to present at BioFinance 2009
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical Announces 2008 Year End Results
7. BioMS Medical warrant extension
8. BioMS Medical to present at BIO CEO and Investor Conference
9. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
10. BioMS Medical recognized at Scrip Awards 2008
11. BioMS Medical Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... SC (PRWEB) , ... April 26, 2017 , ... ... mind, has teamed up with NASA to showcase the future of deep space ... Launch System (SLS) rocket and Orion spacecraft and includes a guest appearance by ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the ... – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by the ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/24/2017)... April 24, 2017  Dante Labs announced today the offer ... 850 (ca. $900). While American individuals have been able to ... Europeans can access WGS below EUR 1,000. The ... leveraging genetic information to make informed decisions about disease monitoring, ... ...
Breaking Biology Technology:
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):